CSBR Champions Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CSBR

Price (delayed)

$5.45

Market cap

$75.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.08

Enterprise value

$75.36M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 21
Relative Valuation: Rel. Valuation: 27
Relative Profitability: Rel. Profitability: 21

Champions Oncology, Inc., formerly Champions Biotechnology, Inc. is a United States-based company that is engaged in the development of advanced technology solutions to personalize the development and use of oncology ...

Highlights
The debt fell by 26% YoY and by 8% QoQ
The company's gross profit rose by 7% QoQ
The net income has plunged by 125% YoY but it has grown by 49% from the previous quarter
The company's EPS has shrunk by 124% YoY but it has surged by 53% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.championsoncology.com
Peers: CRL EXEL CLDX

Key stats

What are the main financial stats of CSBR

CSBR stock price

How has the Champions Oncology stock price performed over time
Intraday
5.83%
1 week
8.57%
1 month
-5.38%
1 year
-21.58%
YTD
-21.13%
QTD
-11.53%

Financial performance

How have Champions Oncology's revenue and profit performed over time
Revenue
$59.43M
Gross profit
$28.53M
Operating income
-$1.14M
Net income
-$1.18M
Gross margin
48%
Net margin
-2%
The company's operating income has shrunk by 125% YoY but it has surged by 57% QoQ
The net income has plunged by 125% YoY but it has grown by 49% from the previous quarter
The net margin has shrunk by 124% YoY but it rose by 49% QoQ
The operating margin has plunged by 124% YoY but it has soared by 58% from the previous quarter

Price vs fundamentals

How does CSBR's price correlate with its fundamentals

Growth

What is Champions Oncology's growth rate over time

Valuation

What is Champions Oncology stock price valuation
CSBR P/E details
P/E
N/A
P/B
19.21
P/S
1.27
EV/EBIT
N/A
EV/EBITDA
168.21
EV/Sales
1.27
The company's EPS has shrunk by 124% YoY but it has surged by 53% QoQ
CSBR's P/B is 75% below its 5-year quarterly average of 71.7 and 21% below its last 4 quarters average of 23.0
Champions Oncology's equity has decreased by 8% QoQ but it has increased by 4.4% YoY
The price to sales (P/S) is 29% lower than the 5-year quarterly average of 1.7 and 25% lower than the last 4 quarters average of 1.6
The revenue has grown by 4.4% YoY and by 2.6% from the previous quarter

Efficiency

How efficient is Champions Oncology business performance
The company's return on invested capital has shrunk by 140% YoY but it has surged by 64% QoQ
The ROA has plunged by 124% YoY but it has grown by 47% from the previous quarter
The company's return on sales has shrunk by 120% YoY but it has surged by 60% QoQ
CSBR's ROE has shrunk by 115% YoY but it is up by 49% QoQ

Dividends

What is CSBR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CSBR.

Financial health

How did Champions Oncology financials performed over time
The total assets is 18% greater than the total liabilities
The total liabilities has contracted by 20% YoY and by 4.8% from the previous quarter
The total assets has declined by 17% year-on-year and by 5% since the previous quarter
The debt is 15% higher than the equity
The debt to equity has contracted by 29% YoY
The debt fell by 26% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.